Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
HMGB1 and inflammatory bowel disease are reported together in 4 articles.
Gene
HMGB1
- HGNC
- HGNC:4983
39articles
39mentions
1variants with confirmed gene link
Most co-reported phenotypes (articles)
diabetes mellitus 6inflammatory bowel disease 4epilepsy 3myocardial infarction 2ulcerative colitis 2COVID-19 1SARS 1arrhythmia 1
Reported variants (articles · ClinVar status)
Phenotype
Inflammatory bowel disease
693articles
693mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
4 records shown · first 60Innovative pH-responsive alginate-coated rosuvastatin-loaded chitosan nanoparticles: a targeted approach to inhibiting HMGB1-activated RAGE/TLR4-NFκB signaling in colonic inflammation in rats.
PMID 40606616 | PMCID PMC12213710 | DOI 10.3389/fphar.2025.1546010 · Frontiers in pharmacology · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | HMGB1 | “Treatment resulted in substantial reductions in key inflammatory markers, including HMGB1, RAGE, TLR4 expression, NFκB activity, pro-inflammatory cytokines (TNF-α and IL-6), and apoptosis marker caspase-3.” | 0.98 | hgnc_dict_v1 |
| phenotype | inflammatory bowel disease | “The goal was to protect RSV-CSNPs from degradation in the acidic gastric environment and facilitate targeted sustained release in the colon to address inflammatory bowel disease.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TLR4 | “Treatment resulted in substantial reductions in key inflammatory markers, including HMGB1, RAGE, TLR4 expression, NFκB activity, pro-inflammatory cytokines (TNF-α and IL-6), and apoptosis marker caspase-3.” | 0.98 | hgnc_dict_v1 |
| phenotype | ulcerative colitis | “These nanoparticles represent a promising strategy for effectively managing ulcerative colitis and related inflammatory bowel diseases.” | 0.98 | phenotype_alias_lexicon_v2 |
Rutin mitigates acetic acid-induced ulcerative colitis: novel coloprotective mechanism.
PMID 39119265 | PMCID PMC11303854 | DOI 10.1093/toxres/tfae108 · Toxicology research · 2024 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | HMGB1 | “Rutin is a natural flavonoid with many pharmacological activities and its role in acetic acid-induced ulcerative colitis through the high mobility group B1 (HMGB1)/ toll-like receptor-4 (TLR4)/ myeloid differentiation primary response protein 88 (MYD88)/ nuclear factor-kB (NF-kB) signaling pathway needs to be explored.” | 0.98 | hgnc_dict_v1 |
| phenotype | inflammatory bowel disease | “BACKGROUND: Ulcerative colitis, an inflammatory bowel disease, is characterized by a status of oxidative stress and inflammation.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TLR4 | “Rutin is a natural flavonoid with many pharmacological activities and its role in acetic acid-induced ulcerative colitis through the high mobility group B1 (HMGB1)/ toll-like receptor-4 (TLR4)/ myeloid differentiation primary response protein 88 (MYD88)/ nuclear factor-kB (NF-kB) signaling pathway needs to be explored.” | 0.98 | hgnc_dict_v1 |
| gene | MYD88 | “Rutin is a natural flavonoid with many pharmacological activities and its role in acetic acid-induced ulcerative colitis through the high mobility group B1 (HMGB1)/ toll-like receptor-4 (TLR4)/ myeloid differentiation primary response protein 88 (MYD88)/ nuclear factor-kB (NF-kB) signaling pathway needs to be explored.” | 0.98 | hgnc_dict_v1 |
Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling.
PMID 33667522 | DOI 10.1016/j.lfs.2021.119295 · Life sciences · 2021 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | HMGB1 | “Notably, no former studies have linked JAK2/STAT3, HMGB1/NF-κB, and Nrf2/HO-1 signaling in TNBS-evoked colitis.” | 0.98 | hgnc_dict_v1 |
| phenotype | inflammatory bowel disease | “Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | JAK2 | “Notably, no former studies have linked JAK2/STAT3, HMGB1/NF-κB, and Nrf2/HO-1 signaling in TNBS-evoked colitis.” | 0.98 | hgnc_dict_v1 |
| gene | STAT3 | “Notably, no former studies have linked JAK2/STAT3, HMGB1/NF-κB, and Nrf2/HO-1 signaling in TNBS-evoked colitis.” | 0.98 | hgnc_dict_v1 |
Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways.
PMID 33412153 | DOI 10.1016/j.cbi.2021.109368 · Chemico-biological interactions · 2021 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | HMGB1 | “Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways.” | 0.98 | hgnc_dict_v1 |
| phenotype | inflammatory bowel disease | “Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | SQSTM1 | “More important, dapagliflozin enhanced colonic autophagy via upregulating Beclin 1 and downregulating p62 SQSTM1 protein expression.” | 0.98 | hgnc_dict_v1 |
| phenotype | myocardial infarction | “Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has featured marked anti-inflammatory effects in murine models of myocardial infarction, renal injury, and neuroinflammation.” | 0.98 | phenotype_alias_lexicon_v2 |